Key facts
- Notable investors include Paladin Capital Group, General Inception, Genoa Ventures, Vertical Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Hermes Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Hermes Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hermes Biosciences
Developer of benchtop extracellular vesicle isolation technology intended to purify exosomes from bodily fluids and cell culture media. The company processes samples directly, and provides reproducible, efficient purification of extracellular vesicles, enabling researchers in oncology, degenerative disease, and regenerative medicine fields to study exosome functions and their potential therapeutic uses.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 7
- Website
- hermesbio.com/
- Ownership
- Privately Held (backing)
Hermes Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hermes Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hermes Biosciences in its N-PORT filings yet. We sweep new filings monthly.